Recent highlights on Omicron as a new SARS-COVID-19 variant: evolution, genetic mutation, and future perspectives

被引:12
作者
Khairnar, Pooja [1 ]
Soni, Mukesh [1 ]
Handa, Mayank [1 ]
Riadi, Yassine [2 ]
Kesharwani, Prashant [3 ]
Shukla, Rahul [1 ]
机构
[1] Natl Inst Pharmaceut Educ & Res Raebareli, Dept Pharmaceut, Lucknow, Uttar Pradesh, India
[2] Prince Sattam Bin Abdulaziz Univ, Coll Pharm, Dept Pharmaceut Chem, Al Kharj, Saudi Arabia
[3] Jamia Hamdard, Dept Pharmaceut, Sch Pharmaceut Educ & Res, New Delhi 110062, India
关键词
Omicron; WHO; SARS-COVID; 19; mutation; vaccination; infection; virus; BINDING; NEUTRALIZATION; COVID-19;
D O I
10.1080/1061186X.2022.2056187
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
COVID-19 has affected the lives of billions of people and is a causative agent for millions of deaths. After 23 months of the first reported case of COVID-19, on 25th November 2020, a new SARS-COVID-19 variant, i.e. Omicron was reported with a WHO tagline of VoC that trembled the world with its infectivity rate. This fifth VoC raised the concern about neutralising ability and adequate control of SARS-COVID-19 infection due to mass vaccination drive (nearly more than 4.7 billion individuals got vaccinated globally till December 2021). However, the present scenario of VoCs highlights the importance of vaccination and public health measures that need to be followed strictly to prevent the fatality from Omicron. The world still needs to overcome the hesitancy that poses a major barrier to the implementation of vaccination. This review highlights the SARS-COVID-19 situation and discusses in detail the mutational events that occurred at a cellular level in different variants over time. This article is dedicated to the scientific findings reported during the recent outbreak of 2019-2022 and describes their symptoms, disease, spread, treatment, and preventive action advised. The article also focuses on the treatment options available for Covid-19 and the update of Omicron by expert agencies.
引用
收藏
页码:603 / 613
页数:11
相关论文
共 54 条
[1]   In-line treatments and clinical initiatives to fight against COVID-19 outbreak [J].
Agrawal, Mukta ;
Saraf, Shailendra ;
Saraf, Swarnlata ;
Murty, Upadhyayula Suryanarayana ;
Kurundkar, Sucheta Banerjee ;
Roy, Debjani ;
Joshi, Pankaj ;
Sable, Dhananjay ;
Choudhary, Yogendra Kumar ;
Kesharwani, Prashant ;
Alexander, Amit .
RESPIRATORY MEDICINE, 2022, 191
[2]   The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms [J].
Alanagreh, Lo'ai ;
Alzoughool, Foad ;
Atoum, Manar .
PATHOGENS, 2020, 9 (05)
[3]   COVID-19: Disease, management, treatment, and social impact [J].
Ali, Imran ;
Alharbi, Omar M. L. .
SCIENCE OF THE TOTAL ENVIRONMENT, 2020, 728
[4]  
Annavajhala MK., 2021, MEDRXIV PREPRINT SER
[5]  
Assessment RR, 2021, ASSESSMENT FURTHER E
[6]  
Banerjee AK., 2020, P INDIAN NATL SCI AC, V86, P1, DOI DOI 10.16943/PTINSA/2020/155490
[7]  
Beddingfield Brandon J, 2021, JACC Basic Transl Sci, V6, P1, DOI [10.1101/2020.06.15.153387, 10.1016/j.jacbts.2020.10.003]
[8]   Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy [J].
Benvenuto, Domenico ;
Angeletti, Silvia ;
Giovanetti, Marta ;
Bianchi, Martina ;
Pascarella, Stefano ;
Cauda, Roberto ;
Ciccozzi, Massimo ;
Cassone, Antonio .
JOURNAL OF INFECTION, 2020, 81 (01) :E24-E27
[9]   Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant [J].
Bernal, Jamie Lopez ;
Andrews, Nick ;
Gower, Charlotte ;
Gallagher, Eileen ;
Simmons, Ruth ;
Thelwall, Simon ;
Stowe, Julia ;
Tessier, Elise ;
Groves, Natalie ;
Dabrera, Gavin ;
Myers, Richard ;
Campbell, Colin N. J. ;
Amirthalingam, Gayatri ;
Edmunds, Matt ;
Zambon, Maria ;
Brown, Kevin E. ;
Hopkins, Susan ;
Chand, Meera ;
Ramsay, Mary .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (07) :585-594
[10]   COVID-19 pandemic da focused review for clinicians [J].
Cevik, M. ;
Bamford, C. G. G. ;
Ho, A. .
CLINICAL MICROBIOLOGY AND INFECTION, 2020, 26 (07) :842-847